Details of the Drug

General Information of Drug (ID: DMTLB92)

Drug Name

DI-Leu16-IL2

Indication

Disease Entry	ICD 11	Status	REF
Non-hodgkin lymphoma	2B33.5	Phase 2	[1]
B-cell lymphoma	2A86	Phase 1/2	[2]
------------------------------------------------------------------------------------

Drug Type

Recombinant protein

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01874288) Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell NHL. U.S. National Institutes of Health.
3	National Cancer Institute Drug Dictionary (drug id 599668).